Editorial

Osteonecrosis of the jaw after treatment with bisphosphonates

BMJ 2006; 333 doi: 10.1136/bmj.39024.647558.BE (Published 9 November 2006)
Cite this as: BMJ 2006;333:982

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Is irreversible, so the focus must be on prevention

  1. Basile Nicolas Landis, resident (Basile.Landis@hcuge.ch),
  2. Michel Richter, professor and head of department,
  3. Ivan Dojcinovic, senior resident,
  4. Max Hugentobler, associate professor
  1. 1Department of Oral and Maxillo-Facial Surgery, University Hospital of Geneva, 1211 Geneva, Switzerland

New generation bisphosphonates such as zolendronic acid, pamidronate, and alendronic acid have various indications in medicine. Initially, their use was restricted to patients with metastatic bone malignancy secondary to breast cancer, lung cancer, prostate cancer, or multiple myeloma. Their benefit in these conditions led to wider application for other bone pathologies, such as osteoporosis and Paget's disease.1 Their main effect is to inhibit osteoclast activity; however, they also seem to have antiangiogenic effects, …

Access to the full text of this article requires a subscription or payment

Subscribe

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

Rapid responses

THIS WEEK'S POLL

BMJ most popular